Raymond James & Associates Zynerba Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 04, 2020	SELL	$3.23 - $4.3 $47,545 - $63,296	-14,720 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$3.31 - $6.54 $48,723 - $96,268	14,720 New	14,720 $50,000
Q3 2019 Nov 07, 2019	SELL	$7.56 - $15.44 $93,025 - $189,989	-12,305 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$5.4 - $15.5 $11,745 - $33,712	2,175 Added 21.47%	12,305 $167,000
Q1 2019 May 06, 2019	SELL	$3.6 - $6.22 $4,809 - $8,309	-1,336 Reduced 11.65%	10,130 $55,000
Q4 2018 Feb 11, 2019	SELL	$2.89 - $7.91 $20,808 - $56,952	-7,200 Reduced 38.57%	11,466 $34,000
Q3 2018 Nov 14, 2018	BUY	$5.59 - $10.45 $10,039 - $18,768	1,796 Added 10.65%	18,666 $152,000
Q2 2018 Aug 14, 2018	BUY	$7.98 - $12.39 $134,622 - $209,019	16,870 New	16,870 $164,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.